Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone44-0-12-3544-3939
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$36.07 million
Profitability
Miscellaneous
Employees60
Next Earnings Date4/10/2019 (Estimated)
OptionableOptionable
SUMMIT THERAPEU/S (NASDAQ:SMMT) Frequently Asked Questions
What is SUMMIT THERAPEU/S's stock symbol?
SUMMIT THERAPEU/S trades on the NASDAQ under the ticker symbol "SMMT."
How were SUMMIT THERAPEU/S's earnings last quarter?
SUMMIT THERAPEU/S (NASDAQ:SMMT) issued its earnings results on Tuesday, December, 11th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.50. The firm earned $0.86 million during the quarter, compared to analysts' expectations of $4.19 million. SUMMIT THERAPEU/S had a return on equity of 1.16% and a net margin of 0.37%. View SUMMIT THERAPEU/S's Earnings History.
When is SUMMIT THERAPEU/S's next earnings date?
What price target have analysts set for SMMT?
8 analysts have issued 12 month target prices for SUMMIT THERAPEU/S's stock. Their forecasts range from $3.00 to $27.00. On average, they expect SUMMIT THERAPEU/S's share price to reach $8.00 in the next year. This suggests a possible upside of 492.6% from the stock's current price. View Analyst Price Targets for SUMMIT THERAPEU/S.
What is the consensus analysts' recommendation for SUMMIT THERAPEU/S?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SUMMIT THERAPEU/S in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for SUMMIT THERAPEU/S.
Has SUMMIT THERAPEU/S been receiving favorable news coverage?
News coverage about SMMT stock has trended positive on Thursday, according to InfoTrie. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. SUMMIT THERAPEU/S earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future.
Who are some of SUMMIT THERAPEU/S's key competitors?
Some companies that are related to SUMMIT THERAPEU/S include Acasti Pharma (ACST), Alimera Sciences (ALIM), Medicure (MCUJF), Melinta Therapeutics (MLNT), Synergy Pharmaceuticals (SGYP), Elite Pharmaceuticals (ELTP), PhaseBio Pharmaceuticals (PHAS), Neos Therapeutics (NEOS), NewLink Genetics (NLNK), IntelGenx Technologies (IGXT), SCYNEXIS (SCYX), Immune Design (IMDZ), AEterna Zentaris (AEZS), Aridis Pharmaceuticals (ARDS) and Tiziana Life Sciences (TLSA).
What other stocks do shareholders of SUMMIT THERAPEU/S own?
Who are SUMMIT THERAPEU/S's key executives?
SUMMIT THERAPEU/S's management team includes the folowing people:
- Mr. Glyn O. Edwards, CEO & Exec. Director (Age 63)
- Prof. David Roblin, COO, Chief Medical Officer and Pres of R&D (Age 53)
- Prof. Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 69)
- Ms. Michelle Avery, Director of Investor Relations
- Richard Pye, Sr. Director of Corp. Affairs & Communications
When did SUMMIT THERAPEU/S IPO?
(SMMT) raised $40 million in an initial public offering (IPO) on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.
Who are SUMMIT THERAPEU/S's major shareholders?
SUMMIT THERAPEU/S's stock is owned by a number of of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (1.32%).
Which major investors are buying SUMMIT THERAPEU/S stock?
SMMT stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC.
How do I buy shares of SUMMIT THERAPEU/S?
Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SUMMIT THERAPEU/S's stock price today?
One share of SMMT stock can currently be purchased for approximately $1.35.
How big of a company is SUMMIT THERAPEU/S?
SUMMIT THERAPEU/S has a market capitalization of $18.68 million and generates $36.07 million in revenue each year. The company earns $-9,280,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. SUMMIT THERAPEU/S employs 60 workers across the globe.
What is SUMMIT THERAPEU/S's official website?
How can I contact SUMMIT THERAPEU/S?
SUMMIT THERAPEU/S's mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company can be reached via phone at 44-0-12-3544-3939 or via email at [email protected]
MarketBeat Community Rating for SUMMIT THERAPEU/S (NASDAQ SMMT)
MarketBeat's community ratings are surveys of what our community members think about SUMMIT THERAPEU/S and other stocks. Vote "Outperform" if you believe SMMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SMMT will underperform the S&P 500 over the long term. You may vote once every thirty days.
